#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic kidney disease Leukocyte adhesion deficiency Cutaneous T-cell lymphoma refractory Bile acid synthesis disorder Urea cycle disorder Idiopathic pulmonary fibrosis Nephropathy Colorectal adenocarcinoma Hypergammaglobulinaemia benign monoclonal Ewing's sarcoma metastatic Glomerulonephritis acute Rhabdomyosarcoma Demyelination Hepatic angiosarcoma Extraskeletal ossification More trials…

    Learn about Rare Diseases

    Familial amyotrophic lateral sclerosis – Diagnostics Synovial sarcoma metastatic – Treatment Lennox-Gastaut syndrome Angelman’s syndrome Isodicentric chromosome 15 syndrome Combined immunodeficiency – Trials in Disease Short-bowel syndrome – Treatment Ewing’s sarcoma – Treatment SAPHO syndrome – Diagnostics Antithrombin III deficiency – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    His203-Crm197 Dabrafenib Mesylate Aficamten Lasmiditan BGB-16673 VANADIUM OXIDE SULFATE Gremubamab Retifanlimab Pirtobrutinib USNOFLAST Ads-011 Paracetamol Ph. Eur. Progesterone Cariprazine Hydrochloride GSKVX000000034796 Flecainide Acetate Quercetin Choriogonadotropin Alfa Iloprost Trometamol Bi 3032950 More therapies…

    Learn about Your Condition

    Diabetes mellitus Piriformis syndrome Ureteric cancer Turner's syndrome Iron deficiency anaemia Benign neoplasm of ureter Facial paresis Sepsis Renal injury Chronic lymphocytic leukaemia Hyperhidrosis HER2 positive gastric cancer Malabsorption Small intestine carcinoma Ocular myasthenia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Laiko General Hospital Of Athens

Laiko General Hospital Of Athens

Messogion Avenue 152, Athens, 115 27, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

    Recruiting

    4 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of IMVT-1402 Treatment for Adults with Graves’ Disease

    Recruiting

    2 1
    Investigated Drugs:
    • IMEROPRUBART
    Bulgaria Czechia Germany Greece Italy Latvia +3

  • Study of anifrolumab safety in adults with primary antiphospholipid syndrome (APS)

    Recruiting

    2 1 1
    Investigated Drugs:
    • Anifrolumab
    Greece

  • Study of depemokimab to improve airway function in patients with type 2 eosinophilic asthma

    Recruiting

    3 1 1
    Investigated Drugs:
    • Depemokimab
    Belgium France Germany Greece Italy Spain

  • Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 mutant non-small cell lung cancer
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Pembrolizumab
    Belgium France Germany Greece Italy Poland +3

  • Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

    Recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Belgium Germany Greece Italy Poland Spain +1

  • Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

    Recruiting

    2 1
    Investigated Drugs:
    • XELAFASLATIDE
    Austria Czechia Germany Greece Hungary Italy +3

  • Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute lymphocytic leukaemia
    • Philadelphia positive acute lymphocytic leukaemia
    Investigated Drugs:
    • Cytarabine
    • Dasatinib
    • Dexamethasone
    Bulgaria Czechia France Germany Greece Hungary +3

  • Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

    Recruiting

    2 1
    Bulgaria Denmark Germany Greece Hungary Italy +2

  • Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cyclophosphamide
    Belgium Czechia Finland France Germany Greece +8
Previous Page
1 … 5 6 7 8 9 … 38
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!